Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 80

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 80
---
%
  
    Other expenses 
     -  
     (630,775) 
     630,775  
     100.0%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     2,900,000  
     (2,900,000) 
     (100.0)%
  
    Stock-based inducement expense 
     (707,300) 
     -  
     (707,300) 
     (100.0)%
  
    Interest income (expense), net 
     13,776  
     (16,977) 
     30,753  
     181.1%
  
    Total other income (expense), net 
     (693,524) 
     2,699,583  
     (3,393,107) 
     (125.7)%

    Net loss 
     (5,417,315) 
     (2,448,654) 
     (2,968,661) 
     121.2%
  
    Deemed dividend on Series A, Series B and C Preferred Stock 
     (24,700,374) 
     -  
     (24,700,374) 
     100.0%
  
    Net loss attributable to common stockholders 
    $(30,117,689) 
    $(2,448,654) 
    $(27,669,035) 
     1,130.0%

Research
and Development Expenses

Research and development expenses were $2,754,000 for the three months
ended June 30, 2025 as compared to $2,714,000 for the three months ended June 30, 2024, reflecting an increase of $40,000. The increase
was primarily attributable to an increase in clinical expenses of approximately $1,056,000 and an increase in scientific consulting fees
of $93,000, offset by a decrease in salaries and benefits of $893,000 primarily due to a decrease in stock-based compensation of $728,000
attributable to a decrease in accretion of stock option expense, and a decrease in lab and other expenses of $216,000. During the first
quarter of 2025, we began clinical trials related to the IND for CER-1236.

The
Company anticipates that